Trial · NCT04570085
Effect of CAFfeine on Cognition in Alzheimer's Disease
NCT04570085, Phase 3, Recruiting, University Hospital, Lille
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of CAFfeine on Cognition in Alzheimer's Disease. Trials, record NCT04570085. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04570085
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of CAFfeine on Cognition in Alzheimer's Disease
- NCT number
- NCT04570085
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 248 participants, estimated
- Lead sponsor
- University Hospital, Lille
- Conditions
- Alzheimer Disease
- Interventions
- Caffeine, Placebo
- First posted
- 2020-09-30
- Last updated
- 2026-04-20
- Other registries' IDs
- eudract:2019-002360-27
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in NTB scores | 30 weeks after randomization | difference between randomized value and value after 30 weeks of treatment |
| Secondary | Caffeine treatment effect on MMSE score | 30 weeks after randomization | difference between randomized value and value after 30 weeks of treatment on MMSE score |
| Secondary | Caffeine treatment effect on NTB subscores | 30 weeks after randomization | difference between randomized value and value after 30 weeks of treatment on NTB subscores |
| Secondary | Caffeine treatment effect on TAP scores | 30 weeks after randomization | difference between randomized value and value after 30 weeks of treatment on TAP scores |
| Secondary | Caffeine treatment effect on Epworth score | 30 weeks after randomization | difference between randomized value and value after 30 weeks of treatment on Epworth score |
| Secondary | Caffeine treatment effect on DAD-6 score | 30 weeks after randomization | difference between randomized value and value after 30 weeks of treatment on DAD-6 score |
| Secondary | Caffeine treatment effect on QoL-AD score | 30 weeks after randomization | difference between randomized value and value after 30 weeks of treatment on QoL-AD score |
| Secondary | Caffeine treatment effect on CGIC score | 30 weeks after randomization | difference between randomized value and value after 30 weeks of treatment on CGIC score |
| Secondary | Caffeine treatment effect on Zarit score | 30 weeks after randomization | difference between randomized value and value after 30 weeks of treatment on Zarit score |
| Secondary | persistent effect of caffeine treatment on MMSE score after a 6 weeks wash out period | 36 weeks after randomization | difference between value after 30 weeks of treatment and value after a 6 weeks wash out period (from Week 30 to Week 36) on MMSE score |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04570085
GET https://conductscience.org/api/trials/v1/NCT04570085/registered?page=2